STOCK TITAN
  1. Home
  2. Sec-filings
  3. GOVX
  4. [8-K] GeoVax Labs, Inc. Reports Material Event

GeoVax (Nasdaq: GOVX) raises $595K, adds new warrant package

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

GeoVax Labs, Inc. entered into a warrant inducement transaction with institutional investors, who agreed to immediately exercise existing warrants to purchase 501,144 shares of common stock for gross cash proceeds of approximately $595,000, before fees and expenses.

In return, the investors will receive new unregistered warrants to purchase up to 1,002,288 shares of common stock at an exercise price of $1.65 per share. The new warrants will become exercisable after shareholder approval of the underlying shares and will expire five years after that approval date. GeoVax engaged A.G.P./Alliance Global Partners as exclusive financial advisor, paying a 7.0% cash fee on gross proceeds and reimbursing up to $40,000 of legal expenses.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Gross proceeds $595,000 From immediate exercise of existing warrants
Existing warrants exercised 501,144 shares Common stock purchased via warrant inducement
New warrant shares 1,002,288 shares Maximum shares issuable under new warrants
New warrant exercise price $1.65 per share Exercise price for new GeoVax warrants
Advisor cash fee 7.0% of gross proceeds Paid to A.G.P./Alliance Global Partners
Legal expense reimbursement cap $40,000 Maximum reimbursable legal costs to advisor
Shareholder meeting deadline June 17, 2026 Target date to obtain stockholder approval
Resale registration timing Within 20 days Deadline to file Form S-1 for new warrant shares
warrant inducement financial
"GeoVax Labs, Inc. announced its entry into a warrant inducement agreement with existing institutional investors"
Warrant inducement is when a company offers new warrants—options to buy shares at a set price—as a sweetener to persuade investors, lenders, or shareholders to approve a deal or provide financing. Investors should care because these extra warrants can dilute existing ownership if exercised, change the company’s future share supply and potential upside, and alter the risk/reward balance much like giving a coupon that could reduce future prices for original buyers.
Regulation D regulatory
"The Company issued the New Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Regulation D"
Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.
private placement financial
"the investors will receive, in a private placement, new unregistered warrants to purchase up to 1,002,288 shares"
A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.
Phase 3 clinical trial medical
"with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026"
A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.
gene-directed enzyme prodrug therapy medical
"Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity"
Form S-1 regulatory
"The Company also agreed to file a registration statement on Form S-1 providing for the resale of the New Warrant Shares"
A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.
Understanding 8-K Material Events →
false 0000832489 0000832489 2026-05-07 2026-05-07
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 
 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  May 7, 2026
 
 
GEOVAX LABS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-39563
87-0455038
(State or other jurisdiction of
incorporation or organization)
(Commission File No.)
(IRS Employee Identification No.)
 
1955 Lake Park Drive, Suite 300
Smyrna, Georgia 30080
(Address of principal executive offices) (Zip code)
 
(678) 384-7220
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
GOVX
The Nasdaq Capital Market
 
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
1
 
 
Item 1.01
Entry into a Material Definitive Agreement.
 
On May 7, 2026, GeoVax Labs Inc. (the “Company”), entered into common stock warrant exercise inducement offer letters (the “Inducement Letters”) with holders (the “Holders”) of existing warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “common stock”), issued on (i) September 30, 2025, which are exercisable for 150,795 shares of common stock (the “September 2025 Warrants”), and (ii) December 22, 2025, which are exercisable for 350,349 shares of common stock (the “December 2025 Warrants” and, together with the September 2025 Warrants, the “Exercised Warrants”), pursuant to which the Holders agreed to exercise for cash their Exercised Warrants to purchase an aggregate of 501,144 shares of the Company’s common stock in consideration for the Company’s agreement to issue new warrants (the “New Warrants”) to purchase an aggregate of up to 1,002,288 shares of the Company’s common stock (the “New Warrant Shares”) with an exercise price of $1.65 per share, exercisable on or after the date on which approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market from the stockholders of the Company with respect to the exercise of the New Warrants and the issuance of all of the Warrant Shares upon exercise thereof and will expire five years following the date of issuance. The Company expects to receive aggregate gross proceeds of approximately $595,000 from the exercise of the Exercised Warrants by the Holders, before deducting financial advisor fees and other offering expenses payable by the Company. The New Warrants are substantially identical to the Exercised Warrants.
 
The Company engaged A.G.P./Alliance Global Partners (“AGP”) to act as its exclusive financial advisor in connection with the transactions summarized above and will pay AGP a cash fee equal to 7.0% of the gross proceeds received from the exercise of the Exercised Warrants. The Company also agreed to reimburse AGP up to $40,000 for its accountable legal expenses in connection with the transaction. The issuance of the New Warrants is expected to occur on May 8, 2026 (the “Closing Date”), subject to satisfaction of customary closing conditions. We expect to use the net proceeds from these transactions for general corporate purposes. The Company has agreed that the Holders shall have the option to exercise the remaining balance of the Exercised Warrants for additional shares of common stock of the Company based on the terms of the Inducement Letters within 12 days from the Closing Date.
 
The resale of the shares of the Company’s common stock issuable upon exercise of the Exercised Warrants are registered pursuant to existing registration statements on Form S-1 (File No. 333-290941), declared effective by the SEC on November 7, 2025, and Form S-1 (File No. 333-292127), declared effective by the SEC on December 19, 2025.
 
The Company also agreed to file a registration statement on Form S-1 providing for the resale of the New Warrant Shares issuable upon the exercise of the New Warrants (the “Resale Registration Statement”), within 20 days of the Closing Date, and to use commercially reasonable efforts to keep the Resale Registration Statement effective at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares. The Company further agreed to hold an annual or special meeting of stockholders on or prior to June 17, 2026, for the purpose of obtaining Stockholder Approval.
 
The forms of the New Warrants and Inducement Letter are filed as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The description of the terms of the New Warrants and Inducement Letters is not intended to be complete and is qualified in its entirety by reference to such exhibits. The Inducement Letters contain customary representations, warranties and covenants by us which were made only for the purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.
 
Item 3.02
Unregistered Sales of Equity Securities.
 
The description of the New Warrants under Item 1.01 of this Form 8-K is incorporated by reference herein. The Company issued the New Warrants pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) available under Regulation D issued thereunder. Neither the issuance of the New Warrants nor the New Warrant Shares have been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.
 
Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy our securities.
 
 
Item 9.01
Financial Statements and Exhibits.
 
 
(d)
Exhibits
 
 
Exhibit No.
Description
 
4.1
Form of Common Stock Purchase Warrant
 
10.1
Form of Inducement Letter, dated May 7, 2026
 
99.1
Press Release
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
2
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: May 7, 2026
 
 
GEOVAX LABS, INC.
  
     
     
 
By:
/s/ Mark W. Reynolds
  
   
Mark W. Reynolds
  
   
Chief Financial Officer
  
       
 
3

Exhibit 99.1

 

logosm.jpg

 

GeoVax Announces a Warrant Inducement Transaction

 

ATLANTA, GA - May 7, 2026 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant inducement agreement with existing institutional investors of the Company for the immediate exercise of existing warrants (the "Existing Warrants") to purchase up to 501,144 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) for gross cash proceeds of approximately $595,000, before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

 

In consideration for the immediate exercise in full of the Existing Warrants, the investors will receive, in a private placement, new unregistered warrants to purchase up to 1,002,288 shares of Common Stock (the “New Warrants”). The New Warrants will have an exercise price of $1.65, will be initially exercisable on the date that shareholder approval of the issuance of the shares of Common Stock issuable upon the exercise of the New Warrants is obtained (the “Approval Date”), and will expire five (5) years following the Approval Date. The closing of the warrant inducement transaction is expected to occur on or about May 8, 2026, subject to satisfaction of customary closing conditions.

 

The private placement of the New Warrants and the shares of Common Stock underlying the New Warrants offered to the institutional investors will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Regulation D promulgated thereunder. Accordingly, the securities issued in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in this Offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

 

About GeoVax

 

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax’s broader pipeline includes the development of GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

 

 
 

 

Forward-Looking Statements

 

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

 

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

 

Company Contact:

info@geovax.com

678-384-7220

 

Media Contact:

Jessica Starman

media@geovax.com

 

 

###

Source: View Original Filing on SEC EDGAR

FAQ

What did GeoVax Labs (GOVX) announce in its warrant inducement deal?

GeoVax Labs announced a warrant inducement transaction where institutional investors will immediately exercise warrants for 501,144 shares, generating about $595,000 in gross proceeds. In exchange, those investors receive new unregistered warrants for up to 1,002,288 additional shares at $1.65 per share.

How much cash will GeoVax Labs (GOVX) receive from the warrant exercise?

GeoVax expects gross cash proceeds of approximately $595,000 from the immediate exercise of existing warrants for 501,144 shares. The company intends to use the net proceeds, after advisor fees and expenses, for working capital and other general corporate purposes as described.

What are the main terms of GeoVax’s new warrants issued in this transaction?

The new warrants allow investors to purchase up to 1,002,288 GeoVax common shares at an exercise price of $1.65 per share. They become exercisable after shareholder approval of the underlying shares and will expire five years after that approval date, according to the disclosure.

How is A.G.P./Alliance Global Partners compensated in the GeoVax warrant deal?

GeoVax engaged A.G.P./Alliance Global Partners as exclusive financial advisor and will pay a 7.0% cash fee on the gross proceeds from exercised warrants. The company also agreed to reimburse A.G.P. up to $40,000 for accountable legal expenses related to the transaction.

How will GeoVax (GOVX) handle registration for shares from the new warrants?

GeoVax agreed to file a Form S-1 registration statement for resale of shares issuable upon exercise of the new warrants within 20 days of closing. The company will use commercially reasonable efforts to keep this registration effective until no new warrants or related shares remain outstanding.

What shareholder actions are required for GeoVax’s new warrants to become exercisable?

The new warrants become exercisable only after shareholder approval of issuing the related common shares. GeoVax agreed to hold an annual or special shareholder meeting on or before June 17, 2026 specifically to obtain this approval for the warrant share issuance.

Filing Exhibits & Attachments

7 documents

Press Releases

Agreements & Contracts

Other Documents